A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2) (NCT05417516)
A Randomized Trial of Five-Fraction Partial Breast Irradiation (RAPID2)
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this study is to determine in women with node negative BC ≤3cm in size, if PBI compared to WBI, both given once-a-day over 1 week following BCS, is non-inferior for LR and reduces adverse cosmesis. The primary outcomes are LR and patient-assessed cosmesis at 3 years post randomization.
Who can join: Review the eligibility criteria below.
Location: GenesisCare Darlinghurst — Darlinghurst, New South Wales
Age range: 50 Years to 120 Years
🧪 Interventions in This Study
- Whole Breast Irradiation (WBI) (RADIATION)
- Partial Breast Irradiation (PBI) (RADIATION)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (30 Sites)
Showing the first 25 of 30 sites.
- GenesisCare Darlinghurst — Darlinghurst, New South Wales
- GenesisCare Hurstville — Hurstville, New South Wales
- GenesisCare Mater Hospital — North Sydney, New South Wales
- GenesisCare Bundaberg — Bundaberg, Queensland
- GenesisCare Southport — Southport, Queensland
- GenesisCare Tugun — Tugun, Queensland
- GenesisCare Hervey Bay — Urraween, Queensland
- GenesisCare St Andrew's — Adelaide, South Australia
- GenesisCare Bedford Park — Bedford Park, South Australia
- GenesisCare Wembley — Wembley, Washington
- GenesisCare Fiona Stanley Hospital — Murdoch, Western Austrailia
- GenesisCare Hollywood — Nedlands, Western Australia
- Arthur J. E. Child Comprehensive Cancer Centre-Clinical Research Unit — Calgary, Alberta
- BCCA-Vancouver Island Cancer Centre — Victoria, British Columbia
- QEII HSC - Nova Scotia Cancer Centre — Halifax, Nova Scotia
- Royal Victoria Regional Health Centre — Barrie, Ontario
- Juravinski Cancer Centre — Hamilton, Ontario
- London Regional Cancer Centre — London, Ontario
- Stronach (Southlake) Regional Health Centre — Newmarket, Ontario
- Algoma District Cancer Program — Sault Ste. Marie, Ontario
- Princess Margaret Hospital — Toronto, Ontario
- Toronto-Sunnybrook Health Sciences Centre - Odette Cancer Centre — Toronto, Ontario
- Windsor Regional Cancer Centre — Windsor, Ontario
- CSSS Champlain - Charles LeMoyne — Greenfield Park, Quebec
- CHUM - Centre Hospitalier de L'Université de Montréal — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (905) 527-2299
Email: schamber@mcmaster.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Neoplasm Female
- Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients — New York, New York
- RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy — St Louis, Missouri
- Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response — Iowa City, Iowa
- The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI — Washington D.C., District of Columbia
Explore by condition: All Breast Neoplasm Female clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.